Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 1 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaccinex Inc | VCNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.9631 | 07:00:09 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.9631 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 1 | - | 4.432 - 100.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 05:55:26 | 1 | $ 5.26 | USD |
Vaccinex Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.79M | 1.17M | - | 570k | -20.25M | -17.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vaccinex News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VCNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.86 | 5.24 | 4.432 | 4.87 | 7,658 | 0.1031 | 2.12% |
| 1 Month | 7.78 | 8.11 | 4.432 | 6.20 | 11,958 | -2.82 | -36.21% |
| 3 Months | 8.89 | 13.02 | 4.432 | 9.97 | 66,317 | -3.93 | -44.17% |
| 6 Months | 13.9272 | 15.9096 | 4.432 | 10.37 | 75,396 | -8.96 | -64.36% |
| 1 Year | 84.00 | 100.80 | 4.432 | 29.97 | 279,944 | -79.04 | -94.09% |
| 3 Years | 516.60 | 688.80 | 4.432 | 222.53 | 328,979 | -511.64 | -99.04% |
| 5 Years | 1,304.10 | 2,568.30 | 4.432 | 694.67 | 587,285 | -1,299.14 | -99.62% |
Vaccinex Description
| Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others. |
